{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:26:42Z","timestamp":1792733202534,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jacc.2013.08.1631","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T01:49:15Z","timestamp":1380246555000},"page":"291-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Left Atrial Appendage Occlusion"],"prefix":"10.1016","volume":"63","author":[{"suffix":"Jr.","given":"David R.","family":"Holmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanunjaya R.","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.08.1631_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cpcardiol.2012.06.001","article-title":"Left atrial appendage occlusion for stroke prevention","volume":"37","author":"Alli","year":"2012","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.08.1631_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for further prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2013.08.1631_bib5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2013.08.1631_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1055\/s-0030-1268861","article-title":"Atrial fibrillation and stroke management: present and future","volume":"30","author":"Holmes","year":"2010","journal-title":"Semin Neurol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000316886","article-title":"Pathophysiological determinants of worse stroke outcome in atrial fibrillation","volume":"30","author":"Tu","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jacc.2013.08.1631_bib9","doi-asserted-by":"crossref","first-page":"610827","DOI":"10.1155\/2012\/610827","article-title":"Left atrial appendage exclusion for stroke prevention in atrial fibrillation","volume":"2012","author":"Patel","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.jacc.2013.08.1631_bib10","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2013.08.1631_bib11","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2013.08.1631_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1538-7836.2010.04085.x","article-title":"A\u00a0comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice","volume":"9","author":"Van Staa","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2013.08.1631_bib13","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.08.1631_bib14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy","volume":"34","author":"Coppens","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.08.1631_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke prevention in atrial fibrillation study: final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.08.1631_bib19","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.08.1631_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.08.1631_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib22","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2013.08.1631_bib24","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.08.1631_bib25","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"Landefeld","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)01401-9","article-title":"Prevalence of atrial fibrillation and eligibility for anticoagulants in the community","volume":"352","author":"Sudlow","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.08.1631_bib29","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1161\/01.STR.28.12.2382","article-title":"Warfarin use among patients with atrial fibrillation","volume":"28","author":"Brass","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2013.08.1631_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and risk Factors in Atrial Fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2008.03059.x","article-title":"Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?","volume":"6","author":"Gallagher","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2013.08.1631_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/eurheartj\/ehl488","article-title":"Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting","volume":"28","author":"Karjalainen","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.08.1631_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ahj.2003.06.004","article-title":"Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation","volume":"147","author":"Orford","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.08.1631_bib36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin inpatients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","article-title":"The Long-Term Multi-Center Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) study","volume":"128","author":"Connolly","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.113.003825","article-title":"New oral anticoagulants in atrial fibrillation forever?","volume":"128","author":"Verheugt","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCULATIONAHA.111.031146","article-title":"Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism?","volume":"125","author":"Granger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2013.08.1631_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib43","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.08.1631_bib44","unstructured":"Majeed A, Hwang HG, Brueckmann M, et\u00a0al. Management and outcomes of major bleeding on dabigatran or warfarin. Abstract presented at: American Society of Hematology Annual Meeting; December 8\u201311, 2012; Atlanta, GA."},{"key":"10.1016\/j.jacc.2013.08.1631_bib45","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1161\/01.CIR.0000015698.54752.6D","article-title":"Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience","volume":"105","author":"Sievert","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib46","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jacc.2007.02.035","article-title":"Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation","volume":"49","author":"Sick","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.08.1631_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib49","first-page":"700","article-title":"Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience","volume":"77","author":"Park","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2013.08.1631_bib50","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","article-title":"Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.08.1631_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.hrthm.2009.11.010","article-title":"Percutaneous left atrial appendage closure with an epicardial suture ligation approach: a prospective randomized pre-clinical feasibility study","volume":"7","author":"Singh","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.08.1631_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jacc.2012.06.046","article-title":"Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience","volume":"62","author":"Bartus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jacc.2011.11.028","volume":"59","author":"Viles-Gonzalez","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib54","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib55","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0735-1097(00)00765-8","article-title":"Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study","volume":"36","author":"Katz","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib56","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jacc.2008.03.067","article-title":"Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography","volume":"52","author":"Kanderian","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.08.1631_bib57","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtcvs.2009.06.033","article-title":"Left atrial appendage clip occlusion: early results","volume":"139","author":"Salzberg","year":"2010","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.08.1631_bib58","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jtcvs.2011.07.052","article-title":"Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial","volume":"142","author":"Ailawadi","year":"2011","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.08.1631_bib59","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.athoracsur.2011.12.077","article-title":"Prospective clinical study of a novel left atrial appendage occlusion device","volume":"93","author":"Slater","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2013.08.1631_bib60","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jacc.2013.03.060","article-title":"The STS-ACC Transcatheter Valve Therapy National Registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies","volume":"62","author":"Carroll","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713053862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713053862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:04:19Z","timestamp":1760015059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713053862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0735109713053862"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.08.1631","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left Atrial Appendage Occlusion","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.08.1631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}